Regulatory updates, research developments, and peptide industry insights
FDA removes 12 peptides from Category 2 restrictions after nomination withdrawals, but compounds remain in regulatory limbo until formal PCAC review determines their legal status for compounding.
Read ArticleThe FDA will convene its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to review seven peptides including BPC-157, TB-500, KPV, and MOTS-C for potential inclusion on the 503A Bulks List. A second meeting before February 2027 will consider five additional peptides including GHK-Cu, Melanotan II, and Cathelicidin LL-37.
Read ArticleThe FDA has officially scheduled Pharmacy Compounding Advisory Committee meetings for July 23-24, 2026 to evaluate seven peptides including BPC-157, TB-500, KPV, and MOTS-C for potential reclassification.
Read ArticleHHS Secretary Kennedy has directed the FDA to reclassify 12 peptides from Category 2 back to Category 1, reversing the 2023 Biden-era restrictions. Here is what it means for the research community.
Read ArticleA clear breakdown of how the FDA classifies peptides under Section 503A, what each category means, and why it matters for researchers and the peptide industry.
Read ArticleNeogenesis Bio Labs
Your first order. Enter your email and we'll
send your code instantly.
Research professionals only • Unsubscribe anytime